- Home
- KTCC vs BLRX Comparison
KTCC vs BLRX Comparison
Compare KTCC & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTCC
- BLRX
- Stock Information
- Founded
- KTCC 1969
- BLRX 2003
- Country
- KTCC United States
- BLRX Israel
- Employees
- KTCC N/A
- BLRX N/A
- Industry
- KTCC Electrical Products
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- KTCC Technology
- BLRX Health Care
- Exchange
- KTCC Nasdaq
- BLRX Nasdaq
- Market Cap
- KTCC 34.0M
- BLRX 15.3M
- IPO Year
- KTCC N/A
- BLRX 2011
- Fundamental
- Price
- KTCC $2.95
- BLRX $4.49
- Analyst Decision
- KTCC
- BLRX Strong Buy
- Analyst Count
- KTCC 0
- BLRX 2
- Target Price
- KTCC N/A
- BLRX $19.00
- AVG Volume (30 Days)
- KTCC 25.7K
- BLRX 190.6K
- Earning Date
- KTCC 08-12-2025
- BLRX 08-14-2025
- Dividend Yield
- KTCC N/A
- BLRX N/A
- EPS Growth
- KTCC N/A
- BLRX N/A
- EPS
- KTCC N/A
- BLRX N/A
- Revenue
- KTCC $483,941,000.00
- BLRX $22,340,000.00
- Revenue This Year
- KTCC N/A
- BLRX N/A
- Revenue Next Year
- KTCC N/A
- BLRX N/A
- P/E Ratio
- KTCC N/A
- BLRX N/A
- Revenue Growth
- KTCC N/A
- BLRX 91.68
- 52 Week Low
- KTCC $2.21
- BLRX $2.30
- 52 Week High
- KTCC $6.14
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- KTCC 55.15
- BLRX 51.09
- Support Level
- KTCC $2.72
- BLRX $4.35
- Resistance Level
- KTCC $2.90
- BLRX $4.64
- Average True Range (ATR)
- KTCC 0.15
- BLRX 0.40
- MACD
- KTCC 0.00
- BLRX -0.07
- Stochastic Oscillator
- KTCC 71.43
- BLRX 47.30
About KTCC Key Tronic Corporation
Key Tronic Corp is an electronic manufacturing service provider. The company provides electronic manufacturing services to original equipment manufacturers in the United States and globally. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly, component selection, sourcing and procurement, logistics, and new product testing and production. The firm derives a majority of its revenue from the United States.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.